An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...

This month we have been discussing mental health and wellness when you have lupus in a four-part blog series. This week we are sharing some strategies on talking about lupus and your experiences.

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

On November 3rd, I ran the New York City Marathon. It was difficult, extraordinary, emotional and painful – not in the least because it was almost 3 years to the day that I got diagnosed with lupus. I ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people ...